Immunelogical diagnosis of MSI-positive gastrointestinal cancer and application for cancer vaccine
Immunelogical diagnosis of MSI-positive gastrointestinal cancer and application for cancer vaccine
批准号:
12470124
负责人:
IMAI Kohzoh
金额:
$8.13万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Microsatellite instability (MSI) due to defective DNA mismatch repair has been shown to play important roles in the development and progression of hereditary nonpolyposis colorectal cancer, a subset of sporadic cancers of the stomach, colorectum, and endometrium, and multiple primary cancers and multicentric cancers. Genetic alterations observed frequently in cancers with MSI are frameshift mutations in mononucleotide tracts present in coding regions of target genes. For example, deletion of one deoxyadenine in the stretch of 10 deoxyadenines in the TGF? Receptor type II gene results in a truncated protein that has 34 new amino acids on its carboxyl end. Many aberrant oligopeptides arise from frameshift mutations of target genes, such as the hMSH3, hMSH6, and BAX genes, in cancers with MSI. These aberrantoligopeptides are highly immunogenic and would be considered by the immune system as a nonself and could induce strong immune response.In support of this hypothesis, we have shown that frameshift mutations of the 2-microblobulin gene are frequently observed in gastric cancers with MSI and that these mutations are associated with unfavorable prognosis. These results suggest that cancers with frameshift mutations of the 2-micro globulin gene are under positive selective pressure for obliterating antigen presentation. Using immunoassay, we were able to detect antibodies directed against aberrant oligopeptides that were generated by frameshift mutations of the target genes in sera of MSI positive gastrointestinal cancer patients. We are also investigating T cell reactions.
期刊论文(72)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Nakamura A., Imai K., et al.: "New classification of intraductal papillary-mucinous tumor by mucin expression"J. Pathol.. 165. 103-110 (2001)
Nakamura A.,Imai K.,et al.:“根据粘蛋白表达对导管内乳头状粘液肿瘤进行新分类”J.
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yamamoto H, Imai K, et al.: "Expression of matrix metalloproteinases and tissue inhibitors of metallo-proteinases in human pancreatic adenocarcinomas : Clinicopathologic and prognostic significance of matrilysin expression"J Clin Oncol. 19. 1118-1127 (200
Yamamoto H、Imai K 等人:“人胰腺腺癌中基质金属蛋白酶和金属蛋白酶组织抑制剂的表达:基质溶素表达的临床病理学和预后意义”J Clin Oncol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Morimoto I, Imai K. et al.: "Identification of the osteopontin gene as a direct target of TP53"Genes Chromosomes & Cancer. (in press). (2002)
Morimoto I、Imai K. 等人:“鉴定骨桥蛋白基因作为 TP53 的直接目标”基因染色体
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Yamamoto H., Imai K. et al.: "Gastrointestinal cancer of the microsatel l ite mutator phenotype pathway"Adv Cancer Res.. (in press). (2002)
Yamamoto H.、Imai K. 等人:“微卫星突变表型途径的胃肠癌”Adv Cancer Res..(正在出版)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Morimoto I., Imai K., et al.: "Identification of the osteopontin gene as a direct target of TP53"Genes Chromosomes & Cancer. (in press). (2002)
Morimoto I.、Imai K. 等人:“鉴定骨桥蛋白基因作为 TP53 的直接靶标”基因染色体
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 36 条
Identification of specific cancer stem cell markers for diagnosis
-
批准号:24650632
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2012
-
负责人:IMAI Kohzoh
-
依托单位:
Development of novel gastrointestinal cancer diagnostic system based on large epige-nome analysis.
-
批准号:23240129
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$31.62万
-
财政年份:2011
-
负责人:IMAI Kohzoh
-
依托单位:
Scientific Support Programs for Cancer Research Grant-in-Aid for Scientific Research on Innovative Areas
-
批准号:221S0001
-
项目类别:Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:IMAI Kohzoh
-
依托单位:
Molecular mechanisms of epigenetic alterations in gastrointestinal cancer and application to diagnosis and therapy
-
批准号:17109008
-
项目类别:Grant-in-Aid for Scientific Research (S)
-
资助金额:$70.89万
-
财政年份:2005
-
负责人:IMAI Kohzoh
-
依托单位:
Immunotherapy using humanized monoclonal antibody
-
批准号:17016060
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$88.7万
-
财政年份:2005
-
负责人:IMAI Kohzoh
-
依托单位:
Microsatellite instability and aberrant methylation in gastrointestinal cancer and its application to molecular target therapy
-
批准号:13854016
-
项目类别:Grant-in-Aid for Scientific Research (S)
-
资助金额:$62.48万
-
财政年份:2001
-
负责人:IMAI Kohzoh
-
依托单位:
Analysis of molecular mechanism of premalignant lesion of the stomach using genomic instability and new mucin gene.
-
批准号:11557043
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$6.91万
-
财政年份:2000
-
负责人:IMAI Kohzoh
-
依托单位:
AnalysIs of molecular mechanism of gastric pre-cancerous lesions by using new mucin genes
-
批准号:09470141
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$2.18万
-
财政年份:1997
-
负责人:IMAI Kohzoh
-
依托单位:
Development of a supersensitive detection method for pancreas cancer associated antigen and tumor suppressor gene by using immuno-PCR.
-
批准号:07557046
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$3.9万
-
财政年份:1995
-
负责人:IMAI Kohzoh
-
依托单位:
Detection of Novel Amyloid-Associated Protein by Monoclonal Antibody and its Gene Analysis
-
批准号:01570363
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1989
-
负责人:IMAI Kohzoh
-
依托单位:
国内基金
海外基金
登录
查看更多内容
MSI2 通过 YTHDF2 介导的m6A 修饰调控CD48/CD244 信号通路促进急性髓系白血病免疫逃逸的机制研究
-
批准号:ZCLQN26H0801
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李帆帆
-
依托单位:
RhoBTB2-Cul3-RBX1介导MSI2泛素化导致儿童神经发育障碍的机制研究
-
批准号:2025JJ60695
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:陈施梦
-
依托单位:
从GPR81/HIF-1 α驱动的MDSC代谢重塑联
合DESI-MSI/AFM策略探讨紫草多糖抑制
CRC进程的药效物质结构和作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:邵萌
-
依托单位:
微卫星不稳定性(MSI)检测试剂盒(基于8个MSI位点、荧光PCR-毛细管电泳法)在结直肠癌真实世界中的应用评价
-
批准号:25SF1906300
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:周晓燕
-
依托单位:
巴氏灭活多形拟杆菌重塑MSI-L结肠癌免疫微环境增敏PD-1抑制剂疗效的机制研究
-
批准号:2025JJ50505
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:贺毅憬
-
依托单位:
达雷木单抗通过清除 CD38+ MDSC 逆转
dMMR/MSI-H 结直肠癌患者免疫耐药的作用
研究
-
批准号:TGY24H160055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:张广文
-
依托单位:
利用深度学习挖掘病理图像特征构建识别胃癌错配修复(MMR)/微卫星不稳定(MSI)状态预测模型
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:张新科
-
依托单位:
MSI2 介导 ITGA2 mRNA 稳定调控骨肉瘤侵袭
转移的机制研究
-
批准号:Q24H160118
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:杨康
-
依托单位:
MSI2/CEBPD/TRIB3 通路调控巨噬细胞极化在 EPA 治疗
子宫内膜异位症中的机制研究
-
批准号:2024JJ6580
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柴小山
-
依托单位:
探索MSI-H肿瘤内源TREX1调控抗肿瘤免疫的机制及相关免疫治疗策略开发
-
批准号:82371848
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2023
-
负责人:韩传辉
-
依托单位: